Candesartan in renal artery stenosis (CARLAS)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN35143689

Enrollment

200

Registered

2007-12-18

Start date

2003-04-15

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal artery stenosis Circulatory System Renal artery stenosis

Interventions

This study is carried out at two centers in Sweden (Göteborg and Malmö). Four weeks after renal angioplasty, all subjects will be randomized to anti-hypertensive treatment with either candesartan (o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Blood pressure above 140 mmHg/90 mmHg 2. Confirmation of renal artery stenosis by either duplex ultrasonography, CT-angiography or MR-angiography

Exclusion criteria

Exclusion criteria: 1. Renal size 80 years 3. Pregnancy or nursing mother 4. Terminal renal failure (Glomerular Filtration Rate [GFR] 1g/day 8. Diabetic nephropathy with tU-alb >0.3 g/day 9. Contraindication for renal angiography/PTRA (eg. serious contrast allergy) 10. Other forms of secondary hypertension 11. Serious malignant disease 12. Treatment with immune-modulating medications eg. cyclosporin and oral steroids

Design outcomes

Primary

Measure	Time frame
Renal function measured by EDTA-clearance and frequency of restenosis 3 years after PTRA.	—

Secondary

Measure	Time frame
Cardiovascular events 3 years after PTRA.	—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026